Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110305 · ClinicalTrials.gov registry record · Phase 2
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
A Phase 2 study, sponsored by Tibotec Pharmaceuticals, Ireland.
- Completed
- Registry status
- Phase 2
- Development phase
- 368
- Enrollment target
NCT00110305 is a Phase 2 study that has completed, run by Tibotec Pharmaceuticals, Ireland. The registered enrollment target is 368 participants.
The verdict
NCT00110305, a Phase 2 study, has completed, sponsored by Tibotec Pharmaceuticals, Ireland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 368 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
Interventions
- DRUG Efavirenz
- DRUG TMC278 25 mg
- DRUG TMC278 75 mg
- DRUG TMC278 150 mg
- DRUG Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2005-06 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110305
The ClinicalTrials.gov registry entry for NCT00110305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tibotec Pharmaceuticals, Ireland, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Efavirenz is the first listed.
NCT00110305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110305 about?
NCT00110305 is a clinical study titled "A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines". The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
What is the current status of trial NCT00110305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 368 participants. The study started on 2005-06. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00110305?
The interventions under investigation include: Efavirenz (DRUG), TMC278 25 mg (DRUG), TMC278 75 mg (DRUG), TMC278 150 mg (DRUG), Non-nucleoside reverse transcriptase inhibitor (NRTIs) (DRUG).
Who is sponsoring clinical trial NCT00110305?
This trial is sponsored by Tibotec Pharmaceuticals, Ireland, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.